Floatz logo

f520

RR DLBCL; PD-1; CD20

Shandong New Time Pharmaceutical Co., LTDPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

107 Active assets in the RR DLBCL; PD-1; CD20 cohort.

Asset / SponsorPhaseRating
Selinexor
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 3BB
DEXAMETHASONE
City of Hope Medical Center
Phase 2/3BB
Ifosfamide
University of California, Davis
Phase 3BB
ETOPOSIDE
University of California, Davis
Phase 3BB
Cyclophosphamide
Nathan Denlinger
Phase 3BB

View all 50 →

Same molecule, other indications

f520 is also rated in:

primary central nervous system lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →
autosomal dominant Parkinson disease 1Dormant
CCC
Indicative ·
53 / 100
View asset →
peripheral T-cell lymphoma, not otherwise specifiedDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →